Cell Source
Business Services · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
57 W 57th St Ste 400, New York City, New...Phone Number
(646) 416-7896Website
www.cell-source.comRevenue
<$5 MillionStock Symbol
CLCSIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Cell Source
Cell Source, Inc. specializes in next-generation immunotherapy, focusing on safer transplantation methods using their innovative Veto Cell protocols. Their therapies address significant challenges in allogeneic transplantations, including donor matching and rejection, while also targeting cancers such as leukemia and lymphoma. The company aims to improve organ transplant acceptance and enhance the quality of life for patients with non-malignant diseases. Their intended clients include patients requiring stem cell transplants, organ transplants, and those suffering from various cancers and autoimmune conditions.Explore more
Cell Source Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cell Source your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Cell Source
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Cell Source is spiking on competitors!
Website visits: Recent activity has been detected on your website
Check if Cell Source has recently received funding, and reach out quickly before it becomes old news!
Click to see if Cell Source had a recent Job posting/layoffs
Earning: See what the market has to say on Cell Source recently announced quarterly report
Product Launch: Get notified when Cell Source launches new products
Cell Source, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Cell Source has new funding data
Recommended Actions
Find VP level buyers at Cell Source
Find more new buyers
Compare Similar Companies to Cell Source
Compare insights from companies similar to Cell Source, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cell Source is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cell Source is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cell Source.
Cell Source Tech Stack
A closer look at the technologies used by Cell Source
See more technologies
Cell Source News & Media
USPTO Issues New Patents for Cell Source's Veto Cell Technology
NEW YORK, March 19, 2021 /PRNewswire/ -- Cell Source, Inc. (OTC: CLCS) ("Cell Source" or the "Company"), the world leader in Veto Cell based innovative immunotherapy technologies that safely facilitate mismatched donor stem cell transplants, e.g. bone marrow transplants (BMT) and organ...Veto T-Cell Bone Marrow Transplant Safely Demonstrates Potential Cure for Sickle Cell Anemia in Preclinical Trials
NEW YORK, March 12, 2021 /PRNewswire/ -- Cell Source, Inc. (OTC: CLCS) ("Cell Source" or the Company"), the world leader in Veto Cell based immunotherapy technologies that can safely facilitate mismatched donor stem cell transplants, e.g. bone marrow transplants (BMT) - in different mouse...Preclinical Data Boosts Case for Cell Source’s CD8+ Veto Cells in BMT
Recently published data from a mouse model of sickle cell disease (SCD) is bolstering the case for the safety of Cell Source’s CD8+ veto cells, currently in Phase I/II testing to improve peripheral blood stem cell transplantation in patients with hematological malignancies.Pediatric Stem Cell Transplantation Expert and Industry Leader Dr. Joseph Rosenthal Joins Cell Source's Scientific Advisory Board
NEW YORK, Feb. 25, 2021 /PRNewswire/ -- Cell Source, Inc. (OTC: CLCS) ("Cell Source" or the "Company"), a developer of Veto Cell-based innovative immunotherapy technologies that facilitate mismatched donor stem cell (e.g. bone marrow) and organ transplants and other cell therapy...
Read more news
Top Business Services Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cell Source
Sign Up For FreeTo access detailed company insights
Cell Source, Inc. specializes in next-generation immunotherapy, focusing on safer transplantation methods using their innovative Veto Cell protocols. Their therapies address significant challenges in allogeneic transplantations, including donor matching and rejection, while also targeting cancers such as leukemia and lymphoma. The company aims to i... Read More
